Prior to joining BeiGene, Ji Li, PhD served as Vice President of Business Development and Licensing at Merck Research Laboratories, a subsidiary of Merck & Co Inc, where he was responsible for business development activities of late-stage inbound and outbound opportunities. In addition, he led the team in executing external clinical collaborations in the immune-oncology space and Merck’s R&D business development efforts in Japan and China. Dr Li was a member of the Board of Directors of BeiGene, as a representative for Merck, up until BeiGene’s IPO in February 2016. Prior to joining Merck, Li was Executive Licensing Director, External R&D at Amgen where he served in various roles in research, business development and licensing for more than 15 years. Dr Li obtained his BS in Pharmacology from Shanghai Medical University and PhD in Neuroscience from Mount Sinai School of Medicine in New York.